Efficacy of Bosentan in treatment of refractory sclerodermic bone prominences skin ulcers.

Abstract

Scleroderma is an autoimmune disease characterized by skin and internal organs involvement. Cutaneous ulcerations is one of the most important complication. It may cause pain, disability and may lead to infections, scarring and amputation. Sclerodermic skin ulcers management is quite complex and involves non-pharmacologic and pharmacologic modalities both for the treatment and the prevention. In this report, authors describe a case of refractory skin ulcerations in a sclerodermic patient treated with endothelin receptor antagonist Bosentan. Bosentan changed the course of cutaneous lesions leading to their complete healing. This treatment represents an alternative therapeutic approach for sclerodermic skin ulcers and it may be taken into consideration for the ongoing development of a new management of cutaneous wounds.

• Authors: A G Richetta, C Mattozzi, E Maiani, S D'Epiro, M Cimillio, V Carboni, S Giancristoforo, S Calvieri
• Journal: La Clinica terapeutica (Clin Ter) 2008 Sep-Oct Vol. 159 Issue 5 Pg. 317-9 ISSN: 1972-6007 [Electronic] Italy
• PMID: 18998033 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antihypertensive Agents
• Endothelin Receptor Antagonists
• Sulfonamides
• Bosentan

Topics

• Administration, Oral
• Aged
• Ankle Joint (pathology)
• Antihypertensive Agents (administration & dosage)
• Bone and Bones
• Bosentan
• Endothelin Receptor Antagonists
• Female
• Humans
• Leg Ulcer (diagnosis, drug therapy, etiology)
• Scleroderma, Systemic (complications, diagnosis, drug therapy)
• Severity of Illness Index
• Sulfonamides (administration & dosage)
• Treatment Outcome
• Wound Healing